Agonist-dependent phosphorylation of the formyl peptide receptor is regulated by the membrane proximal region of the cytoplasmic tail  by Suvorova, Elena S. et al.
Biochimica et Biophysica Acta 1793 (2009) 406–417
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrAgonist-dependent phosphorylation of the formyl peptide receptor is regulated by
the membrane proximal region of the cytoplasmic tail
Elena S. Suvorova, Jeannie M. Gripentrog, Algirdas J. Jesaitis, Heini M. Miettinen ⁎
Department of Microbiology, Montana State University, 109 Lewis Hall, Bozeman, MT 59717, USAAbbreviations: FPR, formyl peptide receptor; C5aR
GPCR, G protein-coupled receptor; fMLF, f-methionine–l
endoglycosidase H; PNGase F, N-glycosidase F; mAb
Chinese hamster ovary; GRK, G protein-coupled recepto
signal-regulated kinase 1/2
⁎ Corresponding author. Tel.: +1 406 994 4014; fax: +
E-mail address: heini@montana.edu (H.M. Miettinen
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.09.011a b s t r a c ta r t i c l e i n f oArticle history: Formyl peptide receptor (FP
Received 8 August 2008
Received in revised form 17 September 2008
Accepted 18 September 2008
Available online 8 October 2008
Keywords:
Chemoattractant receptor
Cell signaling
Desensitization
Protein folding
Cytoplasmic helix 8R) is a chemoattractant G protein-coupled receptor (GPCR) involved in the innate
immune response against bacteria. Receptor activation is terminated by receptor phosphorylation of two
serine- and threonine-rich regions located in the distal half of the cytoplasmic tail. In this study we show that
introduction of an amino acid with a bulky side chain (leucine or glutamine) adjacent to a single leucine,
L320, in the membrane-proximal half of the cytoplasmic tail, signiﬁcantly enhanced receptor phosphoryla-
tion, β-arrestin1/2 translocation, and receptor endocytosis, without affecting Gi-mediated ERK1/2 activation
and release of intracellular calcium. In addition, the point mutations resulted in diminished susceptibility to
trypsin, suggesting a conformation different from that of wild type FPR. Alignment of the FPR sequence with
the rhodopsin sequence showed that L320 resides immediately C-terminal of an amphipathic region that in
rhodopsin forms helix 8. Deletion of seven amino acids (Δ309–315) from the predicted helix 8 of FPR (G307–
S319) caused reduced cell signaling as well as defects in receptor phosphorylation, β-arrestin1/2
translocation and endocytosis. Thus, the amino acid content in the N-terminal half of the cytoplasmic tail
inﬂuences the structure and desensitization of FPR.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionChemoattractant receptors N-formyl peptide receptor (FPR) and
the anaphylatoxin C5a receptor (C5aR), belong to a family of rho-
dopsin-like G protein-coupled receptors (GPCR) [1]. Binding of
exogenous or endogenous N-formylated peptides to FPR, and
complement C5a fragment to C5aR, results in neutrophil migration
from the bloodstream to sites of infection or tissue injury. Upon
exposure to agonist, both receptors undergo a conformational change
that enables binding and activation of G protein. Inactivation of GPCRs
is a multistep process involving phosphorylation of the cytoplasmic
tail, binding of β-arrestin1/2, and receptor endocytosis. The phos-
phorylation takes place on serine and threonine residues in a ligand
concentration-dependent and time-dependentmanner. The phospho-
rylated residues produce a localized concentration of negative charges
that provide one of the binding sites for β-arrestin; the other binding
site is provided through the ligand-binding-induced conformational
change in the receptor [2].
We have previously shown that a dileucine, L318/L319, in the
membrane proximal region of the cytoplasmic tail of C5aR is, anaphylatoxin C5a receptor;
eucine–phenylalanine; EndoH,
, monoclonal antibody; CHO,
r kinase; ERK1/2, extracellular
1 406 994 4926.
).
l rights reserved.important for receptor conformation, phosphorylation and endocy-
tosis [3]. Mutagenesis of leucine 319 into alanine caused protein
retention in the endoplasmic reticulum (ER) of transfected Chinese
hamster ovary (CHO) cells, possibly due to improper protein folding
recognized by the quality control system of the ER [4]. The exchange of
leucine 318 to alanine did not affect protein transport to the plasma
membrane, but caused a defect in receptor phosphorylation, which in
turn reduced receptor internalization [3]. Furthermore, a comparison
of limited proteolysis of wild type C5aR and the C5aR L318A mutant
expressed in CHO cells showed different sensitivity to digestion with
trypsin, suggesting a structural difference between the wild type and
mutant receptor. Thus, the intact dileucine was essential for a protein
structure that supports normal receptor function. (Although dileu-
cines are fairly commonly described as part of an export and/or
internalization signal in GPCRs, the C5aR sequence does not conform
to the classical dileucine-based motifs [5]).
Based on the importance of the dileucine in the function of C5aR,
one might expect that FPR also contains a dileucine in the
corresponding location of the cytoplasmic tail. However, despite 38%
identity and 52% similarity between the cytoplasmic tails of FPR and
C5aR, FPR contains only one leucine (L320) corresponding to L319 in
C5aR [6,7]. Since we have previously observed that the rate of ligand-
induced phosphorylation and endocytosis of FPR is slower than that of
C5aR, we examined whether the introduction of a dileucine in the
corresponding site in FPR (L319/L320, L320/L321) would increase the
rate of phosphorylation. The results from our previous study with
C5aR also supported amodel inwhich the L318/L319 dileucine in C5aR
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region of the cytoplasmic tail. Therefore, we examined the effect of a
seven amino acid deletion (Δ309–315) in the putative helix 8 of FPR on
receptor phosphorylation, β-arrestin1/2 recruitment and receptor
endocytosis. The results from these studies suggested that helix 8 is
required for normal receptor function supported by a dileucine that
promotes rapid receptor phosphorylation, β-arrestin1/2 binding and
receptor endocytosis. Finally, limited proteolysis with trypsin further
corroborated a conformational difference between wild type FPR and
the FPR dileucine mutants. Together, the results from this study lend
further support to our hypothesis that phosphorylation of GPCRs is in
part regulated by receptor conformation involving helix 8 and
surrounding residues.
2. Materials and methods
2.1. Reagents and antibodies
f-Methionine–leucine–phenylalanine (fMLF) was purchased from
Sigma-Aldrich (St. Louis, MO). Trypsin Gold, Mass spectrometry grade
was obtained from Promega Corporation (Madison, WI). Endoglyco-
sidase H (Endo H) and N-glycosidase F (PNGase F) were obtained from
New England Biolabs Inc. (Ipswich, MA). Enhanced chemilumines-
cence (ECL) reagents were from Perkin-Elmer Life Sciences (Boston,
MA). Rabbit monoclonal anti-phospho-p44/42 MAPK (Thr202/
Tyr204) (197G2) antibody was obtained from Cell Signaling Technol-
ogy Inc. (Danvers, MA), and rabbit polyclonal anti-p44/42 MAPK
antibody was from Upstate Cell Signaling Solutions (Lake Placid, NY).
Monoclonal antibody (mAb) NFPR1 and NFPR2 against FPR were
described previously [8]. Rabbit polyclonal antibody against β-
arrestin1/2 was a gift from Robert Lefkowitz (Howard Hughes Medical
Institute and Duke University Medical Center, Durham, NC). Horse-
radish peroxidase (HRP) conjugated goat anti-mouse and anti-rabbit
antibodies were purchased from Jackson ImmunoResearch Labora-
tories Inc. (West Grove, PA). Alexa™ 488-conjugated goat anti-mouse
was obtained from Molecular Probes Inc. (Eugene, OR).
2.2. Oligonucleotide-directed mutagenesis of FPR and CHO
cell transfection
Point mutations of human FPR ([9]; cDNA clone R-26; GenBank
accession no. M60627) were generated by oligonucleotide-directed
mutagenesis using single-stranded DNA template and conﬁrmed by
DNA sequencing (Nevada Genomics Center, University of Nevada–
Reno). cDNAs with a mutation were inserted into pBGSA expression
vector (GenBank accession number AY6607190), which confers G418
resistance [10]. Constructs were transfected into Chinese hamster
ovary (CHO) cells using Lipofectamine™ 2000 transfection reagent
(Invitrogen Life Technologies) according to the manufacturer's
recommendations. CHO cells were cultured in α-modiﬁed Eagle's
medium (α-MEM; Sigma) supplemented with 5% fetal bovine serum
(FBS), 50 U/ml penicillin and 50 μg/ml streptomycin. Stable transfec-
tants were selected with 0.5 mg/ml G418. Twelve to sixteen single
colonies were tested for receptor expression and cellular localization
by immunoﬂuorescence microscopy. Clones of each mutant with
expression levels similar to the wild type receptor were chosen for
further study.
2.3. Indirect immunoﬂuorescence microscopy
CHO transfectants were grown on glass coverslips. In endocytosis
experiments, cells were incubated for 0, 10 or 60 min at 37 °C with
100 nM fMLF before ﬁxation with methanol (mAb NFPR1 does not
bind FPR ﬁxed with paraformaldehyde). Incubations with primary
mAbs NFPR1 and NFPR2 (10 μg/ml) and secondary antibody Alexa™
488-conjugated goat anti-mouse IgG (1:600) were carried out for 1 hat room temperature. The coverslips were mounted in 2.5 mg/ml
DABCO/Glycergel (Sigma) and viewed using a 63× objective on an
Axioskop microscope (Carl Zeiss Inc., Thornwood, NY). The digital
images were adjusted and cropped in Adobe Photoshop.
2.4. Endoglycosidase H and PNGase F digestion
CHO transfectants were scraped from tissue culture plates in PBS
containing a protease inhibitor cocktail (1:1000; P8340, Sigma-
Aldrich) and 1 mM phenyl methyl sulfonyl ﬂuoride (PMSF). Cells
were sedimented by centrifugation, suspended in glycoprotein
denaturation buffer, and denatured for 10 min at 80 °C (higher
temperatures cause aggregation of FPR). Samples were divided into
three tubes and incubated without enzyme or with Endo H or
PNGaseF, according to the manufacturer's instructions. Undigested
and digested FPR were detected by western blot analysis and ECL
using mAb NFPR2 and HRP-conjugated secondary antibody.
2.5. Western blot analysis of FPR phosphorylation
Cells were grown on 35 mm dishes and induced overnight with
6 mM Na butyrate. Cells were stimulated with 100 nM fMLF for 0, 1, 3,
10 or 30min, or for 5minwith 0,1, 3,10, 30,100, 300,1000 or 3000 nM
fMLF, rinsedwith cold PBS and collected in PBS with 1mM PMSF and a
phosphatase inhibitor cocktail (1:100, P2850, Sigma-Aldrich). After
sonication, membranes were sedimented by centrifugation at
21,000 ×g, 20 min, 4 °C. Membranes were solubilized in Laemmli
sample buffer [11] for 20 min at 60 °C, and FPR was detected and
quantiﬁed by conventional western blot analysis or by blot dot
analysis. In conventional western blot analysis, proteins were
separated on a SDS-10% polyacrylamide gel and transferred to a
0.45 μm nitrocellulose membrane using a semi-wet unit (Bio-Rad). In
dot blot analysis, samples were pipetted onto nitrocellulose mem-
branes, dried, and incubated in transfer buffer for 5 min. Western blot
and dot blot membranes were brieﬂy stained in 0.1% Ponceau S in 3%
glacial acetic acid to conﬁrm equal protein loading. The membranes
were blocked in 10% non-fat dry milk in Tris-buffered saline with 0.5%
Tween-20 (TBST) for at least 1 h. After washes with PBS, the
membranes were incubated with primary antibody in TBST containing
5% BSA for 1 h at room temperature or overnight at 4 °C. Total FPR was
detected with mAb NFPR1 and non-phosphorylated FPR was detected
with mAb NFPR2. ECL was carried out as above. The relative quantity
of the proteins was calculated after scanning using Scion image
software (Scion Corporation, Frederick, MA).
2.6. β-Arrestin1/2 assay
Cells grown on 60 mm dishes were stimulated for 5 min with
various concentrations of fMLF (0, 1, 3, 10, 30, 100, 300, 1000 and
3000 nM). After washing with cold PBS, cells were removed by
scraping in 1 ml PBS containing protease inhibitor cocktail (1:1000)
and 1 mM PMSF. Cell suspension was sonicated and the membranes
were sedimented by centrifugation for 15 min 21,000 ×g, 4 °C. The
proteins from the cytosol-containing supernatant were precipitated
by centrifugation in 70% ethanol and both membrane and cytosol
pellets were solubilized for 20 min at 60 °C in Laemmli sample buffer
followed by sonication. β-Arrestin1/2 was detected by western blot
analysis and quantiﬁed as above. Data were analyzed by non-linear
regression analysis using Prism 3.0 software (GraphPad Software, San
Diego, CA).
2.7. Flow cytometry
To measure the relative amount of wild type and mutant FPRs
expressed in the CHO transfectants, cells were incubated for 1 h on ice
in the presence of 40 nM formyl-Norleucine–Leucine–Phenylalanine–
Table 1
Cell surface expression and ligand binding afﬁnity of wild type and mutant FPR
Receptor Receptor
localization
Cell surface
expression (%)
Kd±SD (nM) Citation
FPR wild type PM 100 6±2.0 [12]
FPR Δ309–315 PM 18 2±0.5 [12]
FPR Δ316–322 ER N/A N/A [12]
FPR Δ323–329 ER N/A N/A [12]
FPR A318S/S319L PM 121 4±1.6 This study
FPR S319L PM 76 2±0.5 This study
FPR E321L PM 69 2±0.7 This study
FPR E321Q PM 78 3±0.4 This study
Experiments were carried out as described in the Materials and methods.
Abbreviations: PM, plasma membrane; ER, endoplasmic reticulum; N/A, not available.
Fig. 1. Amino acid sequences of wild type andmutant cytoplasmic tails of FPR. The serine and threonine residues in bold show the phosphorylation sites, as predicted bymutagenesis
experiments [14]. The previously determined primary binding sites of two monoclonal antibodies, NFPR1 and NFPR2, are shown with lines above the amino acid sequence [8]. The
deleted amino acids are indicated with a hyphen (-) and the mutated residues are in bold and underlined.
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Molecular Probes Inc.). Nonspeciﬁc binding was determined in the
presence of 40 μM fMLF. Ten thousand cells were analyzed using
FACScan ﬂowcytometer and nonspeciﬁc binding was subtracted from
total binding. The relative surface expression levels of the mutant
receptors were calculated as percentage of wild type receptor.
The ligand binding Kd values were calculated as previously
described [12]. Brieﬂy, cells were incubated on ice with 50 pM to
40 nM f-NleLFNleYK-ﬂuorescein in the absence or presence of 1000-
fold excess fMLF (background). Cells were analyzed in a FACScan ﬂow
cytometer and the Kd values were determined by least squares
analysis of the mean ﬂuorescence intensity using the Prism software.
To measure receptor internalization, CHO transfectants were
incubated for 15 min with or without 100 nM fMLF and washed
with cold PBS pH 3.0 to remove cell surface ligand. FPR on the cell
surface was detected by FACScan analysis after 45 min incubation on
ice with 20 nM f-NleLFNleYK-ﬂuorescein±20 μM fMLF.
2.8. ERK1/2 activation assay
CHO transfectants were induced overnight with 6 mM Na butyrate
and pre-incubated in serum-free medium for 2 h to reduce ERK1/2
activation by growth factors in the serum. Cells were stimulated with
100 nM fMLF for 0, 2, 5, 10 or 30 min, or for 5 min with 0, 0.1, 0.5, 1.0,
5.0 or 10.0 nM fMLF, rinsed with cold PBS and collected in Laemmli
sample buffer. Cell lysates were analyzed inwestern blots using rabbit
anti-total ERK1/2 and anti-phospho-ERK1/2 antibodies.
2.9. Ca2+ mobilization assay
CHO transfectants were induced overnight with 6mMNa butyrate,
and removed by scraping from tissue culture dishes incubated in Ca2+/
Mg2+-free PBS containing 1 mM EDTA, pH 8.0. Cells were loaded with
2.5 nM Fura 2-AM (Molecular Probes Inc.) in PBS with 5% FBS. Release
of intracellular Ca2+ in response to 0.05, 0.1, 0.25, 0.5, 1 and 5.0 nM
fMLF or 1, 5, 10, 25, 50 and 100 nM fMLF (FPR Δ309–315) was detected
using a double-excitation monochromator ﬂuorescence spectroﬂuo-
rometer, as previously described [13]. The chosen fMLF concentrations
resulted in a range of Ca2+ release from barely detectable to maximal
or near maximal. To determine EC50 values, the relative amount of
fMLF-induced calcium release was calculated by subtracting the
baseline from the fMLF peak value. 10 μM ATP was added as a
heterologous ligand to provide a standard stimulus for calcium
mobilization. Data were analyzed by non-linear regression analysis
using Prism 3.0 software, as previously described [13].
2.10. Limited proteolysis with trypsin
CHO cells expressing wild type and mutant FPR were collected in
PBS containing 1 mM PMSF. After sonication, membranes weresedimented at 21,000 ×g, for 20 min at 4 °C and solubilized in 1%
Triton X-100 in sterile PBS on ice for 1 h. Trypsin stock solution and
dilutions were made according to the manufacturer's recommenda-
tion (Promega Inc., Madison, WI). CHO membranes in duplicates were
treated with increasing concentrations (0–10 ng/μl) of trypsin for 1 h
at room temperature. Proteolysis was stopped by placing samples on
ice for 10 min, adding Laemmli sample buffer and heating at 60 °C for
5 min. Receptor proteolysis was detected by western blotting using
mAb NFPR2. Data were analyzed by non-linear regression analysis
using Prism 3.0 software.
3. Results
3.1. The central part of the cytoplasmic tail of FPR is critical for transport
to the cell surface
To examine the role of the FPR cytosolic tail in receptor function,
we generated a number of deletion and point mutations and
expressed the receptors in Chinese hamster ovary (CHO) cells (Fig. 1
and Table 1). First we analyzed the cellular localization of the deletion
mutants by immunostaining of the cells with anti-FPR antibodies.
Seven residue deletions in the middle of the cytoplasmic tail (FPR
Δ316–322 and FPR Δ323–329) resulted in intracellular retention of
the receptor (Fig. 2A). Another deletion mutation (FPR Δ309–315) was
transported to the cell surface, although immunoﬂuorescence staining
also suggested minor intracellular localization. FPR Δ309–315 was not
recognized by mAb NFPR1, corroborating phage display peptide
analysis results that mapped the antibody binding sites to residues
306–313 [8]. The intracellular retention of FPR Δ316–322 and FPR
Δ323–329 was further conﬁrmed by digestion of their N-linked
glycans. N-glycosylated proteins that are retained in the endoplasmic
reticulum (ER) can be identiﬁed by their sensitivity to endoglycosidase
H (Endo H), an enzyme that cleaves only unprocessed N-linked
glycans characteristic of the ER. After modiﬁcations in the Golgi
complex, the N-glycans become resistant to cleavage with Endo H, but
can be digested by endoglycosidase F (PNGase F). As shown in Fig. 2B,
Fig. 2. Two deletions of seven amino acids near the middle of the cytoplasmic tail of FPR result in protein retention in the endoplasmic reticulum. (A) Immunoﬂuorescence
localization of wild type andmutant FPR in ﬁxed and permeabilized CHO transfectants. FPR was stained with mAb NFPR1 (left column) or mAb NFPR2 (right column), followed by an
Alexa™-488-conjugated secondary antibody. Bar 50 μm. (B) Denatured cell extracts were incubated without enzyme (-) or in the presence of Endoglycosidase H (H) or PNGase F (F).
FPR was detected in western blots with mAb NFPR2.
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Fig. 4. Wild type FPR requires a higher concentration of agonist for half maximal
receptor phosphorylation than the FPR mutants. Western blot analysis of the
concentration dependence of FPR phosphorylation. Cells were incubated for 5 min
with various concentrations of fMLF as shown. FPRwas detected as previously described
(Fig. 3). Non-linear regression analysis of mAb NFPR2 binding to wild type and mutant
FPRs in the presence of various concentrations of ligand. EC50 is shown as mean±SD
from a minimum of three determinations.
Fig. 3.Wild type FPR shows a slower time course of receptor phosphorylation than the
FPR mutants. (A and B) Comparison of the time courses of agonist-induced phos-
phorylation of wild type FPR and the E321L mutant by western blot analysis. Cells were
incubated for the indicated times with 100 nM fMLF. FPR was detected in conventional
immunoblots (A) and dot blots (B) with mAb NFPR2, which does not bind phospho-
rylated receptor, and mAb NFPR1, which binds both non-phosphorylated and phos-
phorylated receptor. (C) Graphic representation of the increase in FPR phosphorylation
shown as the loss of mAb NFPR2 binding to the receptor. FPR phosphorylation was
quantiﬁed from dot blots from a minimum of three experiments. The mean±SD is
shown for each time point.
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H sensitive and the undigested receptors migrated signiﬁcantly faster
through the SDS-polyacrylamide gel than wild type receptor,
suggesting that the N-glycans were not fully processed and therefore
had not passed through the Golgi complex. Deletion of the membrane
proximal seven amino acids (309–315) and mutagenesis at positions
318, 319 and 321 (discussed in more detail below) did not prevent
transport of the mutant receptors to the cell surface (Fig. 2B).
Therefore, we conclude that the middle portion of the FPR carboxyl
tail is likely to play a critical role in maintaining a functional receptor
conformation.Fig. 5. FPR point mutants show enhanced membrane translocation of β-arrestin1/2 in
response to agonist, whereas the FPR Δ309–315 mutant does not induce β-arrestin1/2
translocation. (A) Western blot analysis of fMLF-induced translocation of β-arrestin1/2
to cell membranes from cells expressing wild type and mutant FPR. Cells were
incubated for 5 min in the presence of various concentrations of fMLF. β-Arrestin1/2
from membrane fractions was identiﬁed using a polyclonal antibody. (B) Non-linear
regression analysis of the fMLF concentration dependence of β-arrestin1/2 membrane
translocation. Results were obtained by scanning western blots from a minimum of
three different experiments of each cell line. EC50 is shown as mean±SD from a
minimum of three determinations. (C) The amount of β-arrestin1/2 in the membrane
fraction and the cytoplasmic fraction of CHO FPR wild type and Δ309–315 mutant was
compared. Cells were incubated for 5 min in the presence of various concentrations of
fMLF, as shown. β-Arrestin1/2 from membrane fractions (m) and cytoplasmic fractions
(c) was identiﬁed using a polyclonal antibody, as above.
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next to L320
We recently demonstrated that a dileucine (L318/L319) in the
membrane proximal region of the carboxyl tail of the C5a receptorFig. 6. Enhanced receptor phosphorylation and β-arrestin1/2 membrane translocation corre
were incubated for 15 min at 37 °C in the presence or absence of 100 nM fMLF, washed to
detect FPR remaining on the cell surface. The data are shown as percentage of binding sites on
SD from a minimum of three different experiments. P=0.0057 (non-parametric one-way AN
fMLF. Methanol ﬁxed and permeabilized cells were incubated with mAb NFPR1 and ﬂuoresce
mAb NFPR1 does not bind the mutant receptor.) (C) Immunoﬂuorescence analysis of non
permeabilized cells were incubated with mAb NFPR2 and ﬂuorescent secondary antibody t(C5aR) is important for receptor phosphorylation and folding [3].
Examination of the amino acid sequence of the FPR tail showed a
high similarity with the tail of C5aR, particularly in the membrane
proximal area (Fig. 8). However, a notable difference between the
two receptors is the dileucine found in C5aR (L318/L319), but lackinglate with increased endocytosis. (A) Flow cytometric analysis of endocytosed FPR. Cells
remove remaining ligand, and incubated with a ﬂuorescent formylated hexapeptide to
the cell surface, compared to cells incubated in the absence of fMLF. Data showmeans±
OVA). (B) Immunoﬂuorescence analysis of total FPR after 0 or 10 min incubation with
nt secondary antibody to stain total FPR. (Results for FPR Δ309–315 are not shown since
-phosphorylated FPR after 0, 10 or 60 min incubation with fMLF. Methanol ﬁxed and
o stain non-phosphorylated FPR. Bar 50 μm.
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with the second leucine introduced to the site analogous to C5aR
L318 (FPR S319L) or immediately after the single leucine (FPR E321L)(Fig. 1). We also generated a double FPR mutant A318S/S319L (Fig. 1)
that contained a continuous stretch of ﬁve amino acids in common
with C5aR (315–LPSLL–319). Since the membrane proximal region of
Fig. 8. CHO FPR wild type and CHO FPR E321L show similar calcium curves in response
to fMLF. Cells loaded with Fura 2-AM were induced to release intracellular calcium by
the addition of various concentrations of fMLF at 50 s, as shown.10 μMATPwas added at
100 s to provide a standard stimulus for calcium release.
Table 2
The EC50 values of fMLF-induced intracellular calcium release for wild type and mutant
FPR
Receptor EC50 (nM)
FPR wild type 0.11±0.08
FPR S319L 0.11±0.05
FPR E321L 0.22±0.04
FPR E321Q 0.11±0.12
FPR A318S/S319L 0.10±0.05
FPR Δ309–315 1.70±1.00
413E.S. Suvorova et al. / Biochimica et Biophysica Acta 1793 (2009) 406–417the C5aR is positively charged, we also generated a FPR E321Q
mutant to investigate the effect of removing a negative charge (E)
from the area.
To analyze FPR phosphorylation, we took advantage of monoclonal
anti-FPR antibodies, NFPR1 and NFPR2 [8]. The binding site for mAb
NFPR2 was mapped to the distal part of the carboxyl tail, S338–V345,
which includes two major phosphorylation sites, S338 and T339. We
have previously shown that ligand-induced phosphorylation of FPR
resulted in reduced mAb NFPR2 binding to the receptor [8]. The
reduction of mAb binding was time- and fMLF concentration-
dependent and could be reversed by exposing CHO FPR membranes
to shrimp alkaline phosphatase, indicating that the loss of antibody
binding was indeed due to receptor phosphorylation, rather than
some other physiological change [8]. Thus, we used mAb NFPR2 as a
tool to follow phosphorylation of wild type and mutant FPRs. As
mentioned above, mAb NFPR1 has a major binding site in the
membrane proximal region of the cytoplasmic tail (Q306–I313) and
recognizes phosphorylated and non-phosphorylated receptor equally
well. To quantitatively compare phosphorylation of the mutants with
the wild type receptor, we used a dot blot technique that allows
simultaneous analysis of a large number of samples. Thewestern blotsFig. 7. FPR point mutants show similar activation of ERK1/2 as wild type FPR. (A)Western blot
100 nM fMLF for 0, 2, 5, 10 or 30 min. Phosphorylated ERK1/2 was visualized using an antib
ERK1/2 was visualized using an antibody that recognizes both non-phosphorylated and phos
dependence of ERK1/2 activation. Cells were incubated for 5 min with various concentrati
Quantiﬁcation of the relative amount of phosphorylated ERK1/2 in response to 5 min incuba
three different experiments for each receptor.and the dot blots in Figs. 3A, B show the time course of phosphoryla-
tion in CHO transfectants expressing wild type FPR and the FPR E321L
mutant in the presence of 100 nM fMLF. Wild type FPR shows minor
phosphorylation (decrease in mAb NFPR2 binding) at 1 and 3 min,
whereas phosphorylation of FPR E321L is more pronounced; the
difference is clearly visible after 10 and 30 min incubation.
Quantiﬁcation of the receptors with the NFPR2 antibody showed
that all mutants with a leucine on either side of L320 were more
efﬁciently phosphorylated than the wild type receptor (Fig. 3C). On
the other hand, deletion of amino acids 309–315 completely blocked
receptor phosphorylation, suggesting that this region of the receptor
is required for normal receptor function (Fig. 3C).
To further investigate the phosphorylation, the CHO transfectants
were stimulated for 5 min with increasing concentrations of fMLF.
Consistent with the time course data, all receptors containing a bulky
residue around L320 showed a similar dose-dependence of phosphor-
ylation with EC50s ranging from 7.0 nM (FPR E321Q) to 21.1 nM (FPR
S319L), whereas wild type FPR required a signiﬁcantly higher
concentration for maximal phosphorylation, with an EC50 of 297 nM
fMLF (Fig. 4). Thus, an increase in hydrophobicity in close proximity to
L320 (S321L, A318S/S319L, E321L) appeared to enhance receptor
phosphorylation. The 1.5–3-fold lower EC50 for the FPR E321Q and FPR
E321L mutants, compared to the other dileucine mutants, suggests
that phosphorylation of FPR may be inhibited by the negative charge
at position 321. Removal of the negative charge in combination with
the retention of a bulky side chain (FPR E321Q) appeared to be most
favorable for FPR phosphorylation.
To rule out the possibility that the introduced mutations increased
ligand binding, thereby accelerating receptor phosphorylation, we
determined the receptor Kds (Table 1). The mutants showed similar
binding afﬁnities as wild type FPR. Thus, we conclude that, similar to
C5aR, the membrane proximal region of the FPR tail is involved in
regulation of receptor phosphorylation in the distal portion of the
carboxyl tail.
3.3. Ligand-dependent interaction of the FPR mutants with β-arrestin1/2
Agonist-dependent phosphorylation of many GPCRs is considered
the main regulator of receptor interaction with cytoplasmic scaffold-
ing proteins, β-arrestin1 and 2. Studies of serine and/or threonine
mutants of FPR have demonstrated a complex regulation of FPR
phosphorylation and its effect on β-arrestin1/2 binding [15,16]. We
decided to examine how the FPR mutations that enhanced receptor
phosphorylation would affect the interaction of FPR with β-arrestin1/
2. CHO transfectants were activated for 5 min with different concen-
trations of fMLF. β-Arrestin1/2 translocation to the cell membranewas
monitored by western blot analysis and the quantitative results are
summarized in Fig. 5. All point mutants showed EC50 values loweranalysis of the time course of ERK1/2 activation. Cells were incubated in the presence of
ody that recognizes ERK1/2 phosphorylated on Thr202/Tyr204 (left column) and total
phorylated receptor (right column). (B) Western blot analysis of the fMLF concentration
ons of fMLF, as shown. Phosphorylated and total ERK1/2 was visualized as above. (C)
tion with various concentrations of fMLF. The results are means±SD from a minimum of
Fig. 9. Computational prediction of the helical structure in the membrane proximal
region of the cytoplasmic tail of FPR. Amino acid sequences of bovine rhodopsin (N301–
G328), human C5aR (N296–T324) and human FPR (N297–T325) were aligned (vertical
line) relative to the 7th transmembrane domain (TM7). The position of helix 8 of
rhodopsin is based on the resolved crystal structure [17]. Star (⁎) indicates identical
amino acids in all three sequences. Two dots (:) indicate tolerable amino acid subs-
titutions, and one dot (.) indicates amino acid residues of similar size. The numbers
underlying the sequences represent the rate of conﬁdence for the helical structure
provided by PSIpred and APSS2 servers. A higher number stands for higher conﬁdence.
Hyphen (-) represents the highest conﬁdence of 10, used in the APSS2 prediction.
Dotted line (·····) underlines the sequence of the putative helix 8, as predicted by PSIpred
and APSS2 analysis.
Fig. 10.Wild type FPR is more susceptible to proteolysis than mutant FPRs. Triton X-100 solub
Samples were analyzed in western blots using NFPR2 antibody. (A) Representative wester
quantiﬁed fromwestern blots by scanning. The graph on the left shows the decrease in the am
shows the initial increase and the subsequent decrease in the amount of the proteolytic lo
experiments.
414 E.S. Suvorova et al. / Biochimica et Biophysica Acta 1793 (2009) 406–417than the wild type receptor, corresponding to the results obtained in
the phosphorylation experiments. The difference between the wild
type receptor and the A318S/S319L, E321L and E321Q mutants was
statistically signiﬁcant (Pb0.05), but less dramatic than the difference
detected in phosphorylation. Thus, the mutations in the membrane
proximal region of the cytosolic tail that resulted in enhanced
phosphorylation also led to enhanced binding of β-arrestin1/2. In
the case of the phosphorylation deﬁcient FPR Δ309–315 mutant, we
expected to see no ligand-induced binding of β-arrestin1/2 to the
membrane fractions. This was indeed the case, as shown in Fig. 5C, but
the amount of β-arrestin1/2 in the membrane fraction compared to
the cytosol fractionwas about the same in the absence of ligand (0 nM
fMLF; 40±7%) as in the presence of ligand (10 μM fMLF; 43.7±6.2%).
The equivalent numbers for wild type FPR were 18±5% (0 nM) and 57
±9% (10 μM) [13]. Since FPR Δ309–315 does not become phosphory-
lated, we hypothesize that the deletion of these seven amino acids,
none of which is a phospho-acceptor serine or threonine, results in a
receptor conformation that is favorable for β-arrestin1/2 interaction in
the absence of phosphorylated amino acids. This ﬁnding also suggestsilized membranes of CHO transfectants were treated with 0–10 ng/μl trypsin, as shown.
n blots of the proteolysis of wild type FPR and FPR E321L mutant. (B) Proteolysis was
ount of intact and high molecular weight (HMW) FPR bands and the graph on the right
w molecular weight (LMW) FPR bands. The data are means±SD from three different
415E.S. Suvorova et al. / Biochimica et Biophysica Acta 1793 (2009) 406–417that the lack of receptor phosphorylationmay be at least in part due to
the constitutively bound β-arrestin1/2, which may sterically inhibit
the interaction of other proteins such as G protein and G protein-
coupled receptor kinase (GRK).
3.4. Mutation of the membrane-proximal region of FPR leads to
enhanced agonist-dependent internalization
Internalization of a vast majority of GPCRs requires receptor
phosphorylation, which induces conformational changes necessary
for speciﬁc interactions of the GPCRwith the endocyticmachinery.We
previously showed that a L318A mutation in the carboxyl end of the
putative helix 8 of C5aR resulted in reduced phosphorylation and
internalization [3]. Since reciprocal mutations in the FPR C-tail caused
accelerated phosphorylation of the receptor, we examined the
possibility that this would also enhance receptor endocytosis. First
wemeasured the endocytosis by FACScan analysis: Cells were exposed
to 100 nM fMLF for 15 min, washed, and the receptors remaining on
the cell surface were measured using a ﬂuorescein-conjugated
formylated peptide (f-NleLFNleYK-ﬂuorescein). As shown in Fig. 6A,
all point mutants had less FPR on the cell surface than the wild type
receptor, suggesting more efﬁcient endocytosis (Pb0.01, one-way
ANOVA). In contrast, the FPR Δ309–315 mutant showed no evidence
of endocytosis, corresponding to lack of ligand-induced phosphoryla-
tion and β-arrestin translocation.
Next we examined endocytosis by immunoﬂuorescence micro-
scopy. Immunoﬂuorescence with mAb NFPR1 detected only minor
differences between wild type FPR and the mutants, partly because
the antibody binds both cell surface receptors and internalized
receptors, and the former outshines the latter (Fig. 6B). On the other
hand, mAb NFPR2, which does not bind a phosphorylated receptor,
showed a large difference in staining pattern between wild type FPR
and the mutants after a 10 min exposure to ligand (Fig. 6C).
Whereas wild type FPR appeared to localize at least partly on the
cell surface, the mutants demonstrated very little staining on the
plasma membrane and showed predominantly perinuclear staining
(Fig. 6C). This suggests that most of the mutant receptors on the cell
surface after 10 min stimulation were phosphorylated and did not
bind the antibody. The receptors that had been endocytosed and
dephosphorylated represented the majority of the non-phosphory-
lated receptor. Prolonged continuous exposure (60 min) to the
ligand eliminated the difference, suggesting that a large proportion
of wild type FPR had been phosphorylated on the cell surface and/or
endocytosed and dephosphorylated during the 60 min incubation.
In contrast, FPR Δ309–315 mutant maintained non-phosphorylated
FPR on the cell surface even after 60 min exposure to ligand (Fig.
6C). Therefore, the point mutations in the membrane proximal
region of FPR cytoplasmic tail that resulted in increased phosphor-
ylation and β-arrestin1/2 binding, also led to enhanced receptor
internalization.
3.5. FPR point mutations do not affect G protein-mediated cell signaling
To examine whether the enhanced receptor phosphorylation is
due to changes in intracellular signaling pathways downstream of
Gi, we examined two major signaling pathways; activation of the
downstream kinases ERK1/2, and release of intracellular Ca2+.
Activated (phosphorylated) ERK1/2 was detected in western blots
of whole cell extract after cells were stimulated with 100 nM fMLF
for 0, 2, 5, 10 or 30 min. Both wild type and mutant receptors
showed similar time-dependent activation of ERK1/2, reaching
maximal activation at ∼5 min (Fig. 7A). Upon cell exposure to 0.1,
0.5, 1.0, 5.0 and 10 nM fMLF for 5 min, a similar concentration-
dependence of ERK1/2 activation was observed between the
different CHO transfectants (Fig. 7B). Only FPR Δ309–315 showed
a small delay in phosphorylation of ERK, possibly due to increasedconstitutive β-arrestin1/2 binding (Fig. 5C), which may result in
reduced binding of Gi [12].
We also examined signaling of wild type and mutant FPR by
measuring the EC50 for ligand-binding-induced intracellular calcium
release. Cells were loaded with Fura 2-AM and intracellular calcium
release in response to various concentrations of fMLF was examined.
Representative calcium curves for CHO FPR wild type and CHO FPR
E321L are shown in Fig. 8, and the combined results for all receptors
are presented in Table 2. All CHO FPR mutants with enhanced
phosphorylation showed a similar EC50 for calcium release compared
to wild type FPR (mean values 0.11–0.22 nM), suggesting that the
point mutations did not alter the G protein signaling capacity of the
receptor, an event that takes place prior to receptor phosphorylation
and β-arrestin1/2 binding. The FPR Δ309–315 mutant required
signiﬁcantly higher concentrations of fMLF to induce calcium release
(EC50=1.7±1.0 nM), again corroborating our previous results of
reduced G protein coupling [12].
3.6. Tryptic cleavage data suggest that the FPR mutants are structurally
different from the wild type receptor
The crystal structures of rhodopsin and β2-adrenergic receptor
revealed the presence of a short amphipathic helix in the membrane-
proximal part of the carboxyl tail of these GPCRs [17,18]. Alignment of
this region of rhodopsin with FPR (and C5aR) showed signiﬁcant
similarity in amino acid sequence, suggesting the presence of a similar
structure in FPR (Fig. 9A). Computational prediction analysis of the
amino acid sequence using PSIpred (http://bioinf.cs.ucl.ac.uk/psipred/
psiform.html) [19] and APSS2 (http://imtech.res.in/raghava/apssp/)
servers predicted an α-helix from Q306 to S319 (Fig. 9).
The structure of the carboxyl tail of most other GPCRs is mostly
unknown due to high domain ﬂexibility. Limited digestion of
extracted membrane proteins with trypsin has been used successfully
to study folding of membrane proteins [20]. We therefore decided to
compare wild type FPR and the FPR point mutants by analyzing their
sensitivity to trypsin. Receptors were extracted frommembranes with
Triton X-100 and subjected to digestion with increasing concentra-
tions of trypsin. FPR degradation was detected by western blot
analysis. Wild type FPR was more susceptible to trypsin than the
analyzed mutants (Figs. 10A, B). Degradation of the full-length wild
type FPR led to accumulation of lower molecular weight bands of the
receptor (Figs. 10A, B). All mutants required two- to four-fold higher
concentrations of trypsin to obtain degradation comparable to wild
type FPR. This observation suggests that the tryptic cleavage sites are
less accessible in the mutants, implicating a difference in receptor
folding.
4. Discussion
Structural studies of different members of the GPCR family have
demonstrated that conformational changes play an important role in
the functional regulation of the receptor. Agonist binding to
extracellular loops and transmembrane domains results in an active
receptor conformation which allows further interaction with intra-
cellular partners. Despite many years of intensive study, the secon-
dary structure of the cytosolic regions of GPCRs is still largely
unknown due to their high ﬂexibility. The carboxyl tails of the
rhodopsin-like GPCRs represent the longest intracellular domains
and bear functionally important phospho-acceptor amino acid
residues, serines and threonines. In this study we demonstrated
that agonist-induced phosphorylation of distal sites on FPR is regu-
lated by structural determinants located in the membrane-proximal
region of the tail. Targeted mutagenesis within this region just C-
terminal of the predicted helix 8 revealed the critical importance of
the amino acid content for the structural and functional regulation of
the receptor.
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rhodopsin-like receptors display signiﬁcant differences in their
function [21]. Most relevant to the current study is our observation
that in transfected CHO cells, C5aR becomes maximally phosphory-
lated more rapidly (∼5 min) than FPR (∼30 min) despite similar Kds
(10 nM C5a and 6 nM fMLF, respectively) ([12,21] and this study). We
also showed that disruption of the membrane-proximal dileucine of
C5aR resulted in a decrease in receptor phosphorylation and
endocytosis. The carboxyl tail of FPR shows 38% amino acid identity
with C5aR, but does not contain the analogous dileucine. Introduction
of the reciprocal mutations into FPR resulted in enhanced phosphor-
ylation and endocytosis. Although Kd values for ligand binding to the
dileucine mutants were similar to wild type FPR, the mutant receptors
became more rapidly phosphorylated and required a lower ligand
concentration for maximal phosphorylation (Fig. 3). The increase in
phosphorylation correlated with increased β-arrestin1/2 binding and
receptor endocytosis (Figs. 4–6). The increased rate of phosphoryla-
tion did not appear to be due to differences in common signaling
pathways, since early (2–5 min) activation of ERK1/2 and release of
intracellular calcium in response to ligand gave similar results in CHO
cells expressing wild type and dileucine mutant receptors (Figs. 7 and
8, Table 2). Thus, these ﬁndings led us to conclude that introduction of
a dileucine (S319L/320L; 320L/E321L) or an additional bulky side chain
(320L/E321Q) into FPR on a site analogous to the C5aR dileucine may
play a signiﬁcant role in promoting a receptor structure favorable for
ligand-induced phosphorylation and endocytosis.
Analysis of the sequence in the proximal part of FPR and C5aR tails
suggested the presence of an amphipathic helix similar to helix 8 of
rhodopsin (Fig. 9). Structural stability of the rhodopsin helix 8 is partly
maintained by the presence of one or several cysteines at the COOH-
terminus of the helix [17,22,23]. Lipid modiﬁcation of these cysteines
provides a membrane anchor that helps orient the short amphipathic
helix toward the membrane. However, GPCRs from several sub-
families, including FPR and C5aR do not have cysteines in the
corresponding region, suggesting some other mechanism of mem-
brane interaction. For example, the presence of positively charged
and/or hydrophobic residues at the carboxyl end of helix 8 would
draw the helix to the negatively charged lipid heads in the membrane.
Thus, proteins containing an amphipathic helical binding motif do not
show strict speciﬁcity for one lipid, but respond more generally to a
negative charge. Membrane attachment via lipid anchor may provide
ameans of partitioning the protein into a certainmicrodomain such as
lipid rafts [24,25]. The amphipathic helix of FPR is neutral overall and
thus does not provide a strong interaction with the membrane. The
presence of readily phosphorylated serines on the basic patch raises
the possibility of easy helix detachment from the membrane.
Phosphorylation of these serines will increase the concentration of
negatively charged residues on the cytosolic face and may lead to
repulsion of the helix from the membrane upon receptor phosphor-
ylation. Introduction of the second bulky hydrophobic residue,
leucine, at the COOH-terminus of helix 8 could result in a stronger
interaction of the helix with themembrane. In addition, elimination of
the serine in FPR S319L, and glutamic acid in FPR E321L and FPR E321Q
would reduce the negative charge in the area, further promoting the
interaction with the membrane. Thus, all the point mutations that
were introduced to the cytoplasmic tail of FPR have the potential to
increase the proximity of the N-terminal part of the cytoplasmic tail to
the plasma membrane. This receptor conformation may favor
interaction with intracellular binding partners, such as GRK2, which
interacts with the membrane through a lipid modiﬁcation and has
been shown to phosphorylate FPR [26].
The requirement of receptor phosphorylation in β-arrestin1/2
binding may be variable among different GPCRs. Phosphorylation of
non-visual GPCRs generally results in 2- to 3-fold increase in β-
arrestin, but a bulk negative charge acting as a phosphomimetic may
be as important as the phosphorylated serine or threonine residue inbinding of the positively charged recognition domain on β-arrestin
[2]. FPR Δ309–315 has a slight increase in the net negative charge due
to the loss of two positive charges (R309 and R311) (and one negative
charge [E310]). This increase in negative charge could possibly affect
the afﬁnity of β-arrestin and explain the increased amount of β-
arrestin in the membrane fraction of cells expressing this non-
phosphorylated mutant. The identity and relative position of the
phospho-acceptor amino acids are also important factors in β-arrestin
binding, as would be expected. Mutagenesis studies of FPR showed
that two domains containing serine and threonine residues (S328–
S332 and T334–T339) are required for FPR internalization and
desensitization [27], and further analysis pinpointed phospho-S328,
-S332, and -S338 as critical for β-arrestin binding, internalization, and
desensitization [16]. The high afﬁnity binding of β-arrestin to FPR was
shown to be highly regulated by the phosphorylation status of S328–
S332, while phospho-T334–T339 were more important for endocy-
tosis [14,16]. Our results show that FPR mutants S319L, E321L, E321Q
and A318S/S319L all enhanced receptor phosphorylation, β-arrestin
binding, and endocytosis. Thus, the combination of two hydrophobic
bulky side chains (LL) or one hydrophobic and one neutrally charged
side chain (LQ) immediately C-terminal of putative helix 8, and 7–8
residues N-terminal of S328 appear to increase the rate of interaction
with GRK, suggesting a conformational difference. This hypothesis
was further supported by the ﬁnding that wild type FPR was more
susceptible to proteolytic digestion with trypsin than the mutant
receptors (Fig. 10).
Mutagenesis studies of several GPCRs, including rhodopsin,
protease-activated receptors, and β1-adrenergic receptor, have
shown that helix 8 is directly involved in G protein coupling [28–
31]. We have previously shown that ligand binding to FPR Δ309–315
resulted in 50% reduction in G protein coupling [12]. In this study, we
show that the mutant receptor is also impaired in receptor
phosphorylation, β-arrestin1/2 binding, receptor endocytosis, and
signaling. Thus, our data are consistent with previous results
suggesting a direct contact of helix 8 with the membrane-associated
region of G protein α and γ subunits [28–31]. In addition, this study
and our previous study using C5aR mutants, suggest that helix 8 and
adjacent amino acids coordinate receptor phosphorylation indepen-
dently of receptor signaling.
As the number of studies on GPCR activation, signaling and
desensitization steadily increases, so does our understanding of the
common and receptor-speciﬁc structural elements that are involved in
the regulation. With the known detrimental role played by chemoat-
tractant receptors in pathologies such as rheumatoid arthritis, Crohn's
disease, and ischemia–reperfusion injury, pharmacological targeting
of FPR and C5aR or one of the effector molecules, might greatly
alleviate the destructive effects of neutrophils.
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